Prescient Therapeutics (ASX: PTX) is a clinical-stage oncology company developing PTX-100, a potentially first-in-class inhibitor of GGTase-1, licensed from Yale University. Its lead programme is in Phase 2a for relapsed or refractory cutaneous T-cell lymphoma, a rare and serious blood cancer with limited treatment options. PTX-100 previously showed tumour stabilisation or shrinkage in all reported Phase 1b CTCL patients, with no drug-related serious adverse events reported. A Dose Optimisation Committee review is targeted for December 2026, representing a key clinical and potential partnering catalyst. PTX also sees broader platform potential across RAS-pathway cancers.

• Prescient Therapeutics is seeking to raise up to A$3.0 million through the issue of up to 46.15 million new fully paid ordinary shares.
• Offer price: New shares are being offered at A$0.065 per share.

Discount

• Representing a 4.41% discount to the A$0.068 last traded price on 18 September 2026.
• VWAP discount: The placement price represents a 7.1% discount to PTX’s 30-day VWAP.

Prescient Therapeutics Ltd (ASX: PTX) is an Australian clinical-stage oncology company focused on developing targeted cancer therapies for patients with high unmet medical needs. Its lead asset, PTX-100, is a potentially first-in-class inhibitor of GGTase-1, an enzyme involved in the RAS signalling pathway, which is implicated in a substantial proportion of cancers. The technology was developed at and licensed from Yale University.

PTX-100 is currently in a Phase 2a study for relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and potentially aggressive blood cancer that often manifests in the skin and has limited treatment options. The company reports that Phase 1b CTCL data showed tumour stabilisation or shrinkage in all reported patients, with no drug-related serious adverse events. PTX has enrolled 28 patients in its current study, with 20 evaluable after four treatment cycles. A Dose Optimisation Committee review is expected in December 2026 and may guide the next development stage.

Potential for accelerated commercialisation pathway

• Targeting a market expected to grow to US$ 1.2bn by 2034 in the US alone - based on research by Delveinsight

• Strong regulatory support provides confidence:

  • FDA Fast Track Designation: increased FDA access and rolling submissions of New Drug Application
  • FDA Orphan Drug Designation: 7 years guaranteed market exclusivity in the US
  • EMA Orphan Drug Designation: 10 years guaranteed market exclusivity in the EU

• Now in Phase 2a for Cutaneous T-cell Lymphomas (CTCL)

• Aspiring to turn 2b into a registrational study with the potential for an accelerated pathway to commercialisation, subject to endpoints agreed by the FDA and number of patients required

• 28 patients already enrolled with 20 evaluable (receiving 4 cycles) triggering the first Dose Optimisation Committee (DOC) meeting scheduled for December 2026

Dose Optimisation Committee review represents a key inflection point

• This is the point where big pharma becomes genuinely interested

• Biotech M&A is gaining momentum as big pharma increasingly looks for de-risked assets with near-term commercial potential

• PTX is already in active discussions with both large and mid-tier pharmaceutical companies and seeing meaningful interest

Targeting a deadly cancer of unmet need

• Cutaneous T-cell Lymphomas (CTCL) is a rare and potentially aggressive cancer of white blood cells that manifests primarily in the skin

• Patients with advanced refractory or relapsed CTCL can experience aggressive disease progression with limited treatment options available to them

• Due to its profile as a rare disease of genuine unmet need, many clinicians see the cancer as a “death sentence”

PTX-100 – a first in class targeted therapy with proven results

• Technology was developed by and licensed from Yale University

• A unique compound that inhibits the cancer growth enzyme GGTase-1 - understood to be the only drug of its kind in clinical development worldwide

• Encouraging PTX-100 results shown in Phase 1b trials for CTCL:

  • Clinical Benefit: 100% of patients reporting either tumour halt or shrinkage
  • Safety: Zero drug-related serious adverse events

• Phase 2 goal is to simply replicate, or get close to, PTX-100’s encouraging Phase 1b results

• Platform opportunity:

  • PTX-100 is an inhibitor disrupting the RAS family pathway, which is implicated in 22% of all cancers
  • Its application to CTCL is therefore just one application of Prescient’s technology – which could be applied to many other cancers globally

Case Study:

• Innate Pharma's lead drug lacutamab - targeting Sézary syndrome, a rare form of CTCL (~5% of cases) - won FDA Fast Track in 2019 and Breakthrough Therapy Designation in 2025, and has been cleared for Phase 3 trials. In August 2026, Sobi signed a global license deal worth up to US$580 million: US$75 million upfront, up to US$505 million in near and long term milestones - plus double-digit royalties on top.

• Advance the ongoing development of PTX-100 beyond the Dose Optimisation Committee meeting targeted for December 2026 and progression into the next phase of development;

• General working capital;

• Business development and portfolio management activities which may include the evaluation of complementary pipeline opportunities;

• Costs of the offer